Report of

Key Performance Metrics

For the IRB Review Process

Report #20
Period: January 1, 2014 – June 30, 2014
Posted August 29, 2014

Human Subjects Division
Office of Research
# TABLE OF CONTENTS

## INTRODUCTION
- Background ........................................................................................................... 3
- Metrics Calculations ................................................................................................ 3

## OVERALL TURN-AROUND TIME
- TABLE 1. Overall Turn-Around Time (TAT) for All Initial IRB Applications .......... 4

## DETAILED ANALYSIS: Full IRB Review
- FIGURE 1. Overall Turn-Around Time for Initial Applications Requiring Full IRB Review ............................................................. 5
- FIGURE 2. Distribution of Turn-Around Times for Initial Applications Requiring Full IRB Review .............................................. 6
- FIGURE 3. Time from Application Receipt to First Full IRB Review (“Agenda Date”) ................................................................ 7
- FIGURE 4. Distribution of Outcomes for the First Full IRB Review of Initial Applications .................................................. 8

## DETAILED ANALYSIS: Modifications to Studies Requiring Full Board Oversight
- TABLES 2 AND 3. Turn-Around Time for Modifications to Studies Requiring Full IRB Review ...................................................... 9
- FIGURE 5. Types of Modifications Requested for Studies Requiring Full IRB Review, Reviewed by the convened IRB ....................... 10

## DETAILED ANALYSIS: Minimal Risk Review
- FIGURE 7. Overall Turn-Around Time for Initial Applications Receiving Minimal Risk Review ................................................. 12
- FIGURE 8. Distribution of Turn-Around Times for Initial Applications Receiving Minimal Risk Review .................................. 13
- FIGURE 9. Median Turn-Around Time for Initial Applications for Use of Identifiable Specimens/Data Compared to Initial Minimal Risk Applications .................................................................................. 14

## DETAILED ANALYSIS: Modifications to Minimal Risk Studies
- TABLE 4. Turn-Around Time for Modifications to Minimal Risk Studies .......................................................................................... 15
- FIGURE 10. Types of Modifications Requested for Studies Receiving Minimal Risk Review ............................................................ 16

## DETAILED ANALYSIS: Exempt Applications
- FIGURE 11. Overall Turn-Around Time for Review of Initial Applications for Exempt Status .............................................................. 17
- FIGURE 12. Distribution of Turn-Around Times for Initial Applications for Exempt Status ............................................................ 18

## DETAILED ANALYSIS: Industry Clinical Trials
- TABLE 5. Industry Clinical Trials: Turnaround Times for Specific Start-up Processes ....................................................................... 19

## GLOSSARY OF HSD TERMS ............................................................................. 20

## FREQUENTLY ASKED QUESTIONS .................................................................. 21

## APPENDIX A – IRB PROCESS FLOW CHARTS ............................................. 23
INTRODUCTION

Background
Reliable and detailed metrics are a fundamental tool for accomplishing HSD strategic goals and specific objectives. This regular report fulfills one of those objectives, which is to provide researchers with publicly-available and reliable “turn-around time” metrics, to assist them in planning their research activities. Also, metrics will improve the IRB process by identifying bottlenecks, inefficiencies, and unnecessary steps.

These metrics are updated twice yearly. New metrics calculations will occasionally be added.

Metrics Calculations
Each bi-annual report is based on a 6-month “window” of data.

Three descriptive statistics are reported for turn-around time metrics: median (average) number of business days, range, and number of applications. “Business days” do not exclude University holidays or closures (e.g., snow days).

Additional information
Definitions: page 20
Visual representation of the IRB review process: Appendix A

Questions?
See the “Frequently Asked Questions” at the end of this document.
For other questions, send an email to dora1g@uw.edu
or Lauren White, Metrics and Reporting Specialist, (lawhite@uw.edu).
### OVERALL TURN-AROUND TIME

#### TABLE 1. Overall Turn-Around Time (TAT) for All Initial IRB Applications

<table>
<thead>
<tr>
<th>Reporting Period</th>
<th>Full IRB Review</th>
<th>Minimal Risk Review</th>
<th>Exempt Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range</td>
<td>17 to 274</td>
<td>2 to 243</td>
<td>0 to 129</td>
</tr>
<tr>
<td>Number of Applications (n)</td>
<td>86</td>
<td>387</td>
<td>266</td>
</tr>
<tr>
<td>Target TAT**</td>
<td>71</td>
<td>21</td>
<td>N/A</td>
</tr>
<tr>
<td>Target Upper End of Range**</td>
<td>254</td>
<td>307</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*HSD considers the approval process complete on the date when the approval packet is mailed to the researcher.

**Targets for Turn-Around Time and range have been set using baseline data from 2009. For more information on how the baseline was calculated, please see the Q&A section at the end of this report.

**Note:** Figures and Tables throughout this report contain data for the current reporting period as well as the previous three reporting periods (listed below).

<table>
<thead>
<tr>
<th>Reporting Period</th>
<th>Metrics Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/1/12 – 12/31/12</td>
<td>Report 17</td>
</tr>
<tr>
<td>1/1/13 – 6/30/13</td>
<td>Report 18</td>
</tr>
<tr>
<td>7/1/13 – 12/31/13</td>
<td>Report 19</td>
</tr>
<tr>
<td>1/1/14 – 6/30/14</td>
<td>Report 20</td>
</tr>
</tbody>
</table>
FIGURE 1. Overall Turn-Around Time for Initial Applications Requiring Full IRB Review

**DESCRIPTION**

This figure shows the median number of business days for review and Full Approval of new, initial IRB applications requiring Full Board Review by a convened IRB for the current and previous three reporting periods. The vertical bars show the range of the turn-around times. Horizontal markers show the targeted median and range of turn-around times.
FIGURE 2. Distribution of Turn-Around Times for Initial Applications Requiring Full IRB Review

**DESCRIPTION**
This figure shows the frequency distribution of turn-around times for the review and Full Approval of new, initial applications requiring Full Board Review by a convened IRB during the Reporting Period for Report 20 (1/1/2014-6/30/2014).
FIGURE 3. Time from Application Receipt to First Full IRB Review (“Agenda Date”)

DESCRIPTION
This figure shows the median number of business days between the date a new, initial IRB application requiring Full Board Review is received by HSD and the Agenda Date where it is first reviewed at a meeting of the convened IRB.

Many activities occur during this time period, including:
- Assignment of the application to a specific IRB.
- Creation of a data record in the HSD database.
- Screening of the application (staff read the entire application packet, write a screening email to the researcher, receive and screen the researcher’s response).
- Creation of the meeting agenda (prioritizing workload, assuring that a quorum will be present at the IRB meeting, identifying primary reviewers for each agenda item).
- Preparation and delivery of the agenda materials to the IRB members (staff scan all materials, including screening letters and responses; flash drives with scanned materials are delivered to IRB members).
- IRB members have about 5 business days (per regulations) before the meeting to read and review the materials.

For more information on the process occurring during this period, see section 2.2.3 of the SOP Initial Intake, found on the Policies, Procedures, and Guidance section of HSD’s website.
FIGURE 4. Distribution of Outcomes for the First Full IRB Review of Initial Applications

DESCRIPTION
This figure shows the distribution of outcomes from the first convened IRB meeting for initial applications for the current and previous three reporting periods. As shown, a small number of applications (ranging from 7.5% to 12%) received Full Approval at the first Full IRB meeting, meaning that no subsequent IRB review or action is required. Applications with a review outcome of Deferral (ranging from 43% to 55%) must be reviewed again by the Full IRB after the researcher’s response to the review letter is received. Applications with a review outcome of Conditional Approval (ranging from 40% to 46%) undergo an Expedited Review process (no Full IRB meeting) after the researcher’s response to the review letter is received.
TABLES 2 AND 3. Turn-Around Time for Modifications to Studies Requiring Full IRB Review

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median business days to completion of approval process</td>
<td>23</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>1 to 247</td>
<td>7 to 165</td>
<td>1 to 274</td>
</tr>
<tr>
<td></td>
<td>Number of modifications (n)</td>
<td>122</td>
<td>109</td>
<td>101</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median business days to completion of approval process</td>
<td>6</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>1 to 168</td>
<td>0 to 117</td>
<td>0 to 72</td>
</tr>
<tr>
<td></td>
<td>Number of modifications (n)</td>
<td>847</td>
<td>958</td>
<td>1014</td>
</tr>
</tbody>
</table>

DESCRIPTION
Table 2 shows the turn-around time for Modifications that require review by the full, convened IRB (required when the change is substantive and may alter the risks and/or benefits to subjects). Table 3 shows the turn-around times for Modifications reviewed by a Subcommittee of the IRB, rather than at a convened IRB meeting. Modifications are eligible for Expedited Review via Subcommittee when the proposed changes are minor and will not alter the risks and/or benefits to subjects. Expedited review eligibility can be determined by researchers using the WORKSHEET: Expedited Review Eligibility.
FIGURE 5. Types of Modifications Requested for Studies Requiring Full IRB Review, Reviewed by the convened IRB.

Types of Modifications Requested for Studies Requiring Full IRB Review, Reviewed by the convened IRB

* Types Listed in Order of Descending Frequency

DESCRIPTION

Figures 5 and 6 depict the types of changes requested in Modifications to approved studies requiring Full Board Review. Figure 5 displays the distribution of change types for Modifications reviewed by the Full, convened IRB. Figure 6 shows the distribution of change types for Modifications to studies requiring Full IRB oversight that are reviewed by an IRB Subcommittee using the Expedited process. Modifications are eligible for Expedited Review via Subcommittee when the proposed changes are “minor” and will not alter the risks and/or benefits to subjects.
FIGURE 6. Types of Modifications Requested for Studies Requiring Full IRB Review, Reviewed by the Expedited Process

**Types of Modifications Reviewed by Expedited Process**
(for Studies Requiring Full Board Oversight)

<table>
<thead>
<tr>
<th>Description</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedures</td>
<td>23%</td>
</tr>
<tr>
<td>Consent, Assent Forms</td>
<td>17%</td>
</tr>
<tr>
<td>Recruitment</td>
<td>13%</td>
</tr>
<tr>
<td>Compliance</td>
<td>13%</td>
</tr>
<tr>
<td>Researcher, Staff Change</td>
<td>10%</td>
</tr>
<tr>
<td>Funding</td>
<td>7%</td>
</tr>
<tr>
<td>HIPAA, Confd Agreement</td>
<td>5%</td>
</tr>
<tr>
<td>Population</td>
<td>5%</td>
</tr>
<tr>
<td>Protocol Amend., Invest. Brochure</td>
<td>3%</td>
</tr>
<tr>
<td>Not Defined</td>
<td>1%</td>
</tr>
<tr>
<td>Sites, Locations, Institutions</td>
<td>1%</td>
</tr>
<tr>
<td>Waiver of Consent, Assent</td>
<td>1%</td>
</tr>
<tr>
<td>Waiver of Doc. Of Consent</td>
<td>1%</td>
</tr>
<tr>
<td>Purpose</td>
<td>0%</td>
</tr>
</tbody>
</table>

*Types Listed in Order of Descending Frequency

**DESCRIPTION**
See previous Figure.
FIGURE 7. Overall Turn-Around Time for Initial Applications Receiving Minimal Risk Review

DESCRIPTION
This chart shows the average number of business days required to obtain Full Approval of new, initial IRB applications undergoing Minimal Risk review. The vertical bars show the range of turn-around times. Horizontal markers show the targeted median and range of turn-around times. While the median TAT increased in this reporting period, the range remained well below the target. For more information on Minimal Risk Review, see the SOP Expedited Review on HSD's website.
DESCRIPTION
This figure shows the frequency distribution of turn-around times for the review and approval of new, initial IRB applications undergoing Minimal Risk review during the Reporting Period for Report 20 (1/1/2014-6/30/2014).
FIGURE 9. Median Turn-Around Time for Initial Applications for Use of Identifiable Specimens/Data Compared to Initial Minimal Risk Applications

**Comparison of Median Turn-Around Times**

<table>
<thead>
<tr>
<th>Application Type</th>
<th>Median Business Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applications for Use of Identifiable Specimens/Data</td>
<td>17</td>
</tr>
<tr>
<td>Minimal Risk Applications (n=271)</td>
<td>38</td>
</tr>
</tbody>
</table>

**DESCRIPTION**

This chart compares the turn-around time for “regular” Minimal Risk applications and applications for the Use of Identifiable Specimens/Research. The latter involves the review of medical records or specimens, retrospective or prospective, and does not involve collecting any other information from or about the research subjects. This type of research comprised 42% of this reporting period’s total Minimal Risk applications, and took a median of 17 business days to complete the approval process, compared with 38 business days for other Minimal Risk applications.
TABLE 4. Turn-Around Time for Modifications to Minimal Risk Studies

<table>
<thead>
<tr>
<th>Reporting period</th>
<th>Median business days to completion of approval process</th>
<th>Range</th>
<th>Number of modifications (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report 17</td>
<td>8</td>
<td>0 to 161</td>
<td>473</td>
</tr>
<tr>
<td>7/1/12 – 12/31/12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Report 18</td>
<td>11</td>
<td>0 to 175</td>
<td>558</td>
</tr>
<tr>
<td>1/1/13 – 6/30/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Report 19</td>
<td>6</td>
<td>0 to 205</td>
<td>536</td>
</tr>
<tr>
<td>7/1/13 – 12/31/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Report 20</td>
<td>5</td>
<td>0 to 156</td>
<td>610</td>
</tr>
<tr>
<td>1/1/2014 – 6/30/2014</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DESCRIPTION**

This table shows the median turn-around time in business days for Modifications to Minimal Risk studies for the current and previous three reporting periods.
This figure depicts the types of changes requested in Modifications to approved studies receiving Minimal Risk Review.

*Types Listed in Order of Descending Frequency*
**FIGURE 11. Overall Turn-Around Time for Review of Initial Applications for Exempt Status**

![Median Turn-Around Time Chart]

**DESCRIPTION**
This chart shows the median number of business days required to obtain Exempt Concurrence for Exempt Status Applications for the current and previous three reporting periods. The vertical bars show the range of turn-around times. For more information on Exempt research review, see [SOP: Exempt Determination](#), on HSD's website.
FIGURE 12. Distribution of Turn-Around Times for Initial Applications for Exempt Status

DESCRIPTION
This figure shows the frequency distribution of turn-around times for the review of Exempt Status Applications during the Reporting Period for Report 20 (1/1/2014-6/30/2014).
# TABLE 5. Industry Clinical Trials: Turnaround Times for Specific Start-up Processes

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
<th>Median* (Business Days)</th>
<th>Range (Business Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSD receipt of researcher’s materials</td>
<td>HSD initial screening response</td>
<td>1</td>
<td>0 to 4</td>
</tr>
<tr>
<td>HSD receipt of researcher’s materials</td>
<td>Completion of HSD screening</td>
<td>13¹</td>
<td>0 to 179</td>
</tr>
<tr>
<td>Completion of HSD screening</td>
<td>IRB application submitted to WIRB</td>
<td>4²</td>
<td>0 to 91</td>
</tr>
<tr>
<td>Application received by WIRB</td>
<td>WIRB approval granted</td>
<td>11³³</td>
<td>0 to 67</td>
</tr>
</tbody>
</table>

*Median turnaround times based on about 65 WIRB-reviewed studies that were approved by WIRB during the reporting period for Report 20, (1/1/14 through 6/30/14).

**DESCRIPTION**

¹This step requires information from other offices before HSD can complete its screening and institutional sign-off for WIRB. It includes the time required for:
- HSD’s screening activities;
- Sponsor response time and edits to consent forms and other documents;
- Completion of contract negotiations by the Office of Sponsored Programs (OSP); and
- Completion of the study budget by the Clinical Research Budget and Billing (CRBB) Office.

²This step is performed by the study team and/or study sponsor.

³This step represents the turnaround time for WIRB review.

For more information on reviews conducted by the Western Institutional Review Board, see [SOP WIRB Review, Researcher Procedures](https://www.hsd.org), on HSD’s website.
GLOSSARY OF HSD TERMS

Agenda Date
The date when an application requiring Full IRB Review is first reviewed by a Full IRB at a convened meeting. Also known as the “meeting date”.

Approval
The Full IRB vote or Subcommittee decision to approve an application, with no contingencies or conditions that must be met. Also referred to as Full Approval in this report to distinguish from Conditional Approval.

Approval Date
The date when the Full IRB voted or Subcommittee decided to approve (or Conditionally Approve) an IRB application, except for Exempt Status Applications. For Exempt Applications, the Approval Date is the date when the IRB concurred with the Exemption approval provided by the researcher’s department chair.

Approval Packet
The packet of materials that the IRB sends to the researcher after an application has been fully approved. It includes the formal documentation of IRB approval, typically in a box on the application front page. The Approval Packet also includes the formally-approved and stamped copy of the consent form, which must be used with the research subjects.

Conditional Approval
The Full IRB or Subcommittee decision to approve an application, subject to the fulfillment of minor conditions.

Deferral
The decision (vote) by a Full IRB that indicates the following: (1) the IRB has questions about the research that have bearing upon the risk/benefit analysis of the research; (2) the IRB requires significant additional information or clarification in order to understand specific parts of the application; and/or (3) the IRB is requesting changes to the research in order to address regulatory requirements or concerns arising from the risk/benefit analysis.

Exempt Status
Status granted to studies that involve no more than Minimal Risk and that fall into one or more of the six categories of “Exemption” as defined by Federal regulations. Exempt studies do not require periodic (e.g., annual) re-review.

Follow-up Info Request
A request sent by HSD staff to the researcher requesting specific materials or information (e.g., clean, non-tracked version of consent form) that must be received prior to completion of the approval process.

Full IRB
A review of an application that is performed by a majority of members of the entire IRB (the full board). This level of review is required for all applications that involve more than Minimal Risk to subjects and that do not meet the federally-defined criteria for allowing review by a Subcommittee of the IRB.

Median
The median is a summary measure of the “average” value or central tendency in a set of numbers. To calculate the median: all of the numbers are arranged from lowest value to highest value; the value in the middle is the median. In other words, the median is the point that divides the distribution of scores in half. We use the median instead of the mean because (1) medians are less affected by outlier values in distributions; and (2) turn-around time values are skewed distributions, which are better represented by the median.

Minimal Risk
The term used by the UW for reviews performed by an IRB Subcommittee. Federal regulations use the term “Expedited” review. It can be used only for applications that involve minimal risks to subjects and that meet certain federally-defined criteria.

Modification
Federal regulations require researchers to obtain IRB Review and Approval before making any changes to their already-approved research. The request is submitted to HSD on a Modification form.

Received Date
The date when the printed copies of the IRB application were received by the Human Subjects Division office.

Screening Request
A request sent by HSD staff to the researcher after receipt of a new application to obtain missing information or clarification in order to either a) determine the level of review required (e.g., Expedited versus Exempt), or b) to better prepare the application for Full IRB review.
FREQUENTLY ASKED QUESTIONS

1) Why does it take so long to receive IRB approval?

“Long” is relative, and conducting a quality review takes time. However, HSD has been working successfully to decrease the turn-around time by improving its processes. For example, in 2004 (the last time period for which HSD has metrics), the median turn-around time for Minimal Risk applications was 37 business days, with a range of 0 – 327. A number of factors can add to the time required:

- Completeness of the initial application – did everything that is required for review come in with the application when first submitted to HSD and were all questions fully and appropriately answered?
- Complexity of the application – studies that involve multiple subject groups; use new methodologies and/or research techniques; require multiple stages and/or study sites; and/or raise significant ethical and/or safety issues can require additional time to review.
- Specific regulatory requirements – studies that involve vulnerable subjects or that use approaches for which there are specific regulatory requirements can require additional time to review to assure that all requirements are met by the researcher and the IRB.
- Applications that are Deferred require preparation of, and response to, an often lengthy review letter, followed by a second review by a full IRB at one of its bi-weekly meetings.
- Applications that need to be transferred to a different level of review (for example, from Minimal Risk to Full IRB), or that have been submitted on the wrong type of application form.
- A considerable amount of available Minimal Risk review time is spent communicating with researchers about IRB applications that are eventually determined to not require IRB review because the described activities do not meet the federal regulatory definition of Human Subjects Research.

The IRB is responsible for continuing review and oversight of about 6,300 currently approved and active studies, each with its own IRB application.

2) Your Metrics Report says the median number of business days to conditionally approve a Full IRB new application is 24 business days. Why is my application taking longer?

“Median” means that half of the applications will take less than 24 business days to obtain Conditional Approval and half of the applications will take more than 24 business days. Any individual application may be impacted by the factors described above in Question #1. Delays in responding to questions or requests from the IRB can also contribute to the overall time required for review.
3) Is there anything I can do to speed my application through the approval process?

Yes – the following recommendations can help to decrease the time required for review of your application:

- Always use the most current forms directly from the HSD web site [http://www.washington.edu/research/hsd/forms/] and read thoroughly the instructions on each form.
- If you have questions as you are completing an IRB application, contact an appropriate HSD Administrator (see the HSD contact webpage) or send an email to hsdinfo@uw.edu with a brief description of the research or issue and your question, or request a telephone or in-person consult. This can improve the application and potential turn-around time.
- To the extent possible – make sure that your application is complete. Include all necessary documentation and complete all questions asked. If a question on the application does not apply to your research, at least indicate “NA” or “Not Applicable.” **Do not leave questions blank.**
- When you receive questions or requests for additional information/materials from the IRB – respond as quickly and thoroughly as possible.
- If you are a student, make sure that you involve your faculty advisor in each step of the IRB submission process, including responding to requests and correspondence from the IRB.
- If you are a Faculty Advisor, be involved in each step of your students’ IRB submission process.
- Find out if there is someone in your department who is designated to assist colleagues with preparing IRB applications and consult with that person prior to submitting your application.

4) Will these turn-around times improve in the future?

HSD puts significant effort and resources into strategic planning and process improvement efforts designed to make the IRB review process more efficient, consistent, and transparent. The results of these efforts are shown by comparing the metrics reported across our quarterly reports.

5) Is one IRB faster than another, and how do I get my application placed with that committee?

The review of one IRB is not necessarily faster than that of another. Over time, the average turn-around time across the IRBs is about the same. At any given point, each individual IRB is affected by increased or decreased volume of applications; complexity and quality of applications; staffing; and availability of IRB members. Applications for both Full Board and Minimal Risk review are generally assigned to review teams based on the Principal Investigator’s academic department.

6) How many HSD staff work on a single application? Or, how many IRBs are there?

There are six IRBs at the UW for which HSD provides administrative support – four review biomedical research and two review social/behavioral research. The UW IRBs also have six subcommittees (Minimal Risk teams) that review Minimal Risk and Exemption applications. At least two HSD staff members typically work on each individual application.

7) How was the baseline calculated?

The baseline for the turn-around time metrics for new applications requiring full IRB review, new applications for Minimal Risk review, and applications for Exempt status, was derived by tracking all new applications received between July 1, 2008 and December 31, 2008, until each reached a final status of either approved or closed. For those that reached a status of Full Approval, the turn-around time was calculated as the business days from the date received at HSD to the date the approval packet was sent to the researcher, whenever that occurred. As a result, both the median and the range for full IRB and Minimal Risk applications are higher for the baseline cohort than for the other reporting period cohorts, as the baseline includes more applications that took an exceptionally long time for review. For an explanation of reasons why review and approval can take longer than the median, please see Question 1 above in this section. Additionally, the applications included in the baseline will have been in earlier metrics reports, depending on when the approval packet was sent to researchers.
Figure 1: Process for Initial Application Requiring Full IRB Review

1. Application received
2. Initial processing, data entry, limited screening, assignment to IRB
3. Full IRB Committee teams
4. Item screened, screening letter sent to PI
5. PI response to screening received
6. Item assigned to agenda
7. Item reviewed by full IRB & decision made
8. Write letter notifying PI of decision
9. Letter emailed to PI
10. PI response to deferral or conditional approval received
11. Response reviewed by full IRB or subcommittee
12. PI approval given to item? Yes or No
13. YES: Approval packet sent to PI
14. NO: Overall Turn-around Time

Time to first Full IRB Meeting

Figure 2: Process for Initial Applications Receiving Minimal Risk Review

1. Application received
2. Initial processing, data entry, limited screening, assignment to IRB
3. Minimal risk review
4. Item screened and/or reviewed, screen/review letter sent to PI
5. PI response to screen/review letter received
6. Approval
7. Approval packet sent to PI

Overall Turn-around Time
APPENDIX A – IRB PROCESS FLOW CHARTS, (cont’d)

Figure 1: Process for Review of Exempt Research Applications

Application received

Initial processing, data entry, limited screening, assignment to IRB

Review

Item screened and/or reviewed, screen/review letter sent to PI

PI response to screen/review letter received

Exempt? Yes or No

Certificate of Exemption

Approval packet sent to PI

Overall Turnaround Time

Exempt?

Yes or No

Not exempt, PI notified

Figure 1: Process for Review of Exempt Research Applications